Antihemophilic factor (recombinant)

(Advate®)

Antihemophilic factor (recombinant)

Drug updated on 9/14/2023

Dosage FormInjection (intravenous; 250, 500, 1000, 1500, 2000, 3000 or 4000 IU)
Drug ClassRecombinant antihemophilic factor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For use in children and adults with hemophilia A for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Product Monograph / Prescribing Information

Document TitleYearSource
Advate (antihemophilic factor (recombinant)) Prescribing Information.2023Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA

Systematic Reviews / Meta-Analyses